INmune Bio Reports Improved White Matter Integrity in Phase 2 Alzheimer’s Trial of INB03

INmune Bio reported statistically significant improvements in white matter integrity among patients with Alzheimer’s disease following the completion of its Phase 2 MINDFuL clinical trial. The study utilized magnetic resonance imaging (MRI) to track changes in brain structure, identifying a measurable treatment effect in participants who received the company’s experimental therapy, INB03.

Researchers monitored the progression of white matter hyperintensities—areas of the brain often associated with cognitive decline—to evaluate the drug’s impact. The data indicated that patients treated with the therapy showed a distinct difference in these biomarkers compared to those in the control group. The trial focused on assessing whether the intervention could mitigate the structural damage typically observed in Alzheimer’s patients. These findings provide a quantitative look at how the treatment influences brain health, marking a primary endpoint in the company’s ongoing investigation into the drug’s efficacy.

Newsflash | Powered by GeneOnline AI

Source: GO-AI-ne1

For any suggestion and feedback, please contact us.

Date: June 2, 2026

Author

GOAI